ALMS logo

ALMSAlumis Inc.

$20.06
$0.05
(0.25%)
Today
Closed $20.06
$0.11
(0.55%)
After Hours
Updated: 07:19 PM EDT
Reported EarningsMay 14
Mkt Cap$2.55B
Vol1.18M
News
all
press releases
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter
Key PointsDeep Track Capital bought 6,772,595 shares of Alumis last quarter; the estimated transaction value was $169.31 million (based on average prices...
Nasdaq News: Markets
News Placeholder
More News
News Placeholder
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter
Key PointsCormorant bought 313,645 additional Alumis shares in the first quarter; the estimated trade size was $7.84 million (using average prices in the quarter...
Nasdaq News: Markets
News Placeholder
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back
Key PointsOmega Fund Management sold 411,968 shares of Alumis; the estimated trade value is $10.3 million (based on quarterly average price...
Nasdaq News: Markets
News Placeholder
This Alumis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Top analysts changed outlook on top names. See all rating changes on analyst ratings page. Check out analysts' views on ALMS stock.read more...
Benzinga
News Placeholder
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates
C4 Therapeutics (CCCC) delivered earnings and revenue surprises of +4.76% and -5.35%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Why One Fund's $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug
Key PointsACT Capital Management acquired 174,250 ALMS shares in the first quarter, with an estimated trade value of $4.36 million based on average first-quarter pricing...
Nasdaq News: Markets
News Placeholder
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates
Personalis (PSNL) delivered earnings and revenue surprises of -26.09% and +7.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Alumis Inc. (NASDAQ:ALMS) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Alumis Inc. (NASDAQ:ALMS - Get Free Report) has been assigned an average rating of "Moderate Buy" from the twelve analysts that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, ten have given a buy rating and one has assigned a strong buy...
MarketBeat
News Placeholder
Alumis Inc. (NASDAQ:ALMS) Short Interest Up 25.3% in March
Alumis Inc. (NASDAQ:ALMS - Get Free Report) was the target of a large increase in short interest during the month of March. As of March 31st, there was short interest totaling 11,230,693 shares, an increase of 25.3% from the March 15th total of 8,963,277 shares. Based on an average daily trading...
MarketBeat
News Placeholder
Alumis Inc. $ALMS Shares Sold by Trium Capital LLP
Trium Capital LLP lessened its stake in Alumis Inc. (NASDAQ:ALMS - Free Report) by 71.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.